PRESS-RELEASE filed Nov 13, 2026 at 16:05 ET
Indaptus Therapeutics reported Q3 2026 net loss of $1.0M ($0.01 per share), narrowed from $3.0M ($2.98) a year ago, driven by an 82% reduction in R&D spending to $0.3M as the company winds down its Decoy20 clinical program. The company raised $24M in a September private placement and is pivoting to early-stage research on a neurotechnology device for sleep conditions, a strategic shift away from its core immunotherapy pipeline.